Activated DCs release the damage-associated molecular pattern known as HMGB1 (high-mobility group box 1), which stimulates T and B cell responses while inhibiting innate immune responses to tumor-derived nucleic acids. The gene discussed is HMGB1; the disease is neoplasm.